Literature DB >> 22478774

Comparative effectiveness: the employer perspective.

Marc B Royo.   

Abstract

Biopharmaceuticals are rapidly emerging as a focal point of concern in benefit design. CE initiatives may prove their value, but controlling costs will be up to consumers.

Year:  2009        PMID： 22478774      PMCID： PMC2799081     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  7 in total

1.  Employers work to manage biologics in 2008 benefit designs.

Authors:  Amanda Brower
Journal:  Biotechnol Healthc       Date:  2007-12

2.  Why employers need to rethink how they buy health care.

Authors:  Robert S Galvin; Suzanne Delbanco
Journal:  Health Aff (Millwood)       Date:  2005 Nov-Dec       Impact factor: 6.301

3.  Medicare and cost-effectiveness analysis.

Authors:  Peter J Neumann; Allison B Rosen; Milton C Weinstein
Journal:  N Engl J Med       Date:  2005-10-06       Impact factor: 91.245

Review 4.  Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII.

Authors:  Walter H Dzik
Journal:  J Intensive Care Med       Date:  2006 Jan-Feb       Impact factor: 3.510

5.  Between a rock and a hard place: understanding the employer mind-set.

Authors:  Robert S Galvin; Suzanne Delbanco
Journal:  Health Aff (Millwood)       Date:  2006 Nov-Dec       Impact factor: 6.301

6.  Health benefits in 2008: premiums moderately higher, while enrollment in consumer-directed plans rises in small firms.

Authors:  Gary Claxton; Jon R Gabel; Bianca Dijulio; Jeremy Pickreign; Heidi Whitmore; Benjamin Finder; Marian Jarlenski; Samantha Hawkins
Journal:  Health Aff (Millwood)       Date:  2008-09-24       Impact factor: 6.301

7.  What's fueling the biotech engine?

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908
  7 in total
  1 in total

Review 1.  Exosome and its roles in cardiovascular diseases.

Authors:  Wang Zhao; Xi-Long Zheng; Shui-Ping Zhao
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.